Anthem Biosciences Ltd Technical Momentum Shifts Signal Bullish Outlook

Price Performance and Market Context

On 21 July 2026, Anthem Biosciences Ltd closed at ₹791.55, marking a 1.99% increase from the previous close of ₹776.10. The stock traded within a range of ₹781.70 to ₹807.40 during the day, demonstrating intraday strength. Its 52-week high stands at ₹873.25, while the 52-week low is ₹579.45, indicating a substantial recovery and upward momentum over the past year.

Comparatively, Anthem Biosciences has outperformed the Sensex significantly over the year-to-date period, delivering a 21.58% return against the Sensex’s negative 8.81%. Over the past week, the stock surged 5.92%, dwarfing the Sensex’s modest 0.12% gain. This relative strength highlights growing investor confidence in the company amid a challenging market backdrop.

Technical Indicator Analysis

The technical landscape for Anthem Biosciences has improved markedly. The Moving Average Convergence Divergence (MACD) indicator on the weekly chart is bullish, signalling positive momentum and potential continuation of the uptrend. Although the monthly MACD remains neutral, the weekly bullishness suggests near-term strength.

The Relative Strength Index (RSI) on the weekly and monthly charts currently shows no definitive signal, indicating the stock is not yet overbought or oversold. This neutral RSI suggests room for further price appreciation without immediate risk of a technical pullback.

Bollinger Bands on the weekly timeframe are bullish, with the price approaching the upper band, reflecting increased volatility and a strong upward price move. This often precedes sustained momentum if supported by volume and other indicators.

Daily moving averages have turned bullish, with the stock price trading above key averages, reinforcing the positive trend. This alignment of moving averages typically attracts momentum traders and institutional interest.

Additional Technical Signals and Trend Assessments

The Know Sure Thing (KST) indicator on the weekly chart remains mildly bearish, suggesting some caution in the short term. However, this is offset by the Dow Theory weekly trend, which is mildly bullish, indicating that the broader market structure supports the stock’s upward movement.

On balance volume (OBV) analysis shows no clear trend on the weekly chart but a mildly bullish signal on the monthly chart, implying that accumulation may be occurring over a longer horizon. This accumulation phase is often a precursor to sustained price rallies.

Mojo Score Upgrade and Market Capitalisation

Reflecting the improved technical outlook, Anthem Biosciences’ Mojo Score has risen to 78.0, earning a Buy grade as of 21 May 2026. This marks a significant upgrade from its previous Sell rating, signalling enhanced confidence from MarketsMOJO’s proprietary scoring system. The company is classified as a mid-cap stock within the Pharmaceuticals & Biotechnology sector, a segment that has shown resilience and growth potential amid evolving healthcare demands.

The upgrade in Mojo Grade is supported by the stock’s technical trend change from mildly bullish to bullish, reinforcing the positive momentum narrative. Investors should note that this rating incorporates a comprehensive analysis of price action, volume, and technical indicators, providing a robust framework for decision-making.

Long-Term Returns and Sector Comparison

While short-term technicals are encouraging, Anthem Biosciences’ longer-term returns also merit attention. The stock has delivered a 21.58% return year-to-date, outperforming the Sensex’s negative 8.81%. Over three years, the Sensex has returned 15.00%, and over five years 48.87%, but Anthem’s recent momentum suggests it is positioning itself well to capture further gains in the pharmaceutical and biotechnology space.

Given the sector’s importance in innovation and healthcare, Anthem’s technical strength may attract investors seeking exposure to mid-cap growth opportunities with improving fundamentals and technicals.

Investor Considerations and Outlook

Despite the encouraging technical signals, investors should remain mindful of certain cautionary factors. The mildly bearish KST on the weekly chart and the neutral RSI readings suggest that while momentum is positive, the stock may experience intermittent consolidation phases. Additionally, the pharmaceutical sector can be sensitive to regulatory developments and clinical trial outcomes, which may impact price volatility.

However, the alignment of multiple bullish indicators—weekly MACD, daily moving averages, and Bollinger Bands—combined with the Mojo Score upgrade, provides a compelling case for investors to consider Anthem Biosciences as a growth candidate in the mid-cap space. The stock’s ability to outperform the Sensex year-to-date further strengthens this view.

Technical traders may find opportunities in the current bullish trend, particularly if the stock sustains above key moving averages and breaks decisively above recent intraday highs. Long-term investors should monitor fundamental developments alongside technical momentum to gauge the sustainability of gains.

Summary

Anthem Biosciences Ltd has transitioned into a bullish technical phase, supported by strong price momentum, positive MACD signals on the weekly chart, and bullish daily moving averages. The stock’s recent outperformance relative to the Sensex and the upgrade to a Buy Mojo Grade reflect growing market confidence. While some indicators advise caution, the overall technical and market context favours continued upside potential for this mid-cap pharmaceutical player.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →